MTOR and ovarian carcinoma: Similarly, Caumanns et al. reported that low‐dose triple‐drug combinations targeting the PI3K/AKT/mTOR and MAPK signaling pathways resulted in cumulative kinase activity inhibition and diminished tumor growth without inducing toxicities in ovarian carcinoma cells [38].